Line-blot (immunoblot) to prove specific IgM and IgG antibodies against the pathogens involved in TORCH syndrome. The test is suitable for both screening and confirmation. TORCH syndrome includes the most common infectious agents leading to pregnancy pathology, including: T – Toxoplasma gondii, O-other - other pathogens, including Parvovirus B19, Treponema pallidum, VZV, etc., R – Rubella virus, C - cytomegalovirus and H – Herpes simplex virus type 1 and 2). II. Methods of determination The test allows, with one analysis, to examine antibodies of the IgM or IgG class against all pathogens involved in the TORCH syndrome at the same time. III. Clinical significance and informative content Infectious agents involved in TORCH syndrome are one of the main causes of pathological pregnancy. In the mother, the infection can occur before or during pregnancy, and infections are usually asymptomatic or with mild clinical symptoms. Infection of the fetus occurs with primary or reactivated infection in the mother, and the mechanisms of infection of the fetus are transplacental, perinatal (from vaginal secretions or blood) or postnatal (from breast milk or other sources). As a result, the following may occur: growth retardation, congenital malformations (affecting a number of organs and systems, including the cardiovascular and nervous systems, vision, hearing, etc.), miscarriage, premature or stillbirth. The risk of developing a primary infection in the fetus is usually inversely proportional to the gestational age. So e.g. the riskiest is infection during the first trimester of pregnancy, with a large percentage of cases remaining undiagnosed as they end in spontaneous abortion by 12 weeks of gestation. When the mother's primary infection occurs in the third trimester of pregnancy, the risk of transplacental transmission is very high higher – from 75 to 80%. Unlike primary infection, persistent or reactivated infection does not pose such a serious risk to the fetus. In this case, only 5 to 10% of newborns become infected. The risk of intrauterine transmission of CMV during pregnancy is significantly greater in women who develop primary infection postconception than in women with evidence of infection (circulating CMV antibodies) before pregnancy. recomLine TORCH IgG The use of recombinant antigens allows the following information to be obtained in one diagnostic test:
- Unnumbered listToxo lysate- the presence or absence of these antibodies determines the immune status to Toxoplasma gondii.
- Toxo p30 - determine the time since the beginning of the infection, and their presence is an indicator of an infection more than 3 months old
- Rubella WHO control-gives information about the presence of protective immunity
- Rubella lysate - the presence of these antibodies determines the immune status to the rubella virus
- CMV lysate- antibodies determine immune status to CMV
- CMV gB2 - their presence is an indicator of an infection more than 6-8 weeks old
- HSV-1/2 lysate - these antibodies determine the immune status to HSV
- HSV-2 gG2 – prove HSV-type 2 infection
- recomLine TORCH IgM:
1. Allows identification with one reaction of specific IgM antibodies against Toxoplasma gondii, Rubella, CMV, HSV 1 and 2 2. The purpose of the analysis is to confirm positive and ambiguous results when proving an acute infection with the given pathogen. IV.Indications: The TORCH IgG/IgM test is recommended for screening in women of reproductive age preconception or as soon as possible after the diagnosis of pregnancy, to determine their immune status and possible asymptomatic infection. The test is recommended for all equivocal results, obtained from other screening studies for each of the pathogens included in the panel. The test enables monitoring of seronegative women during pregnancy and, accordingly, timely therapy in case of primary infection of the mother. Determines the time since the beginning of the infection, differentiating acute, reactivated, passed or suspected infection.
